{
  "ticker": "MIRM",
  "company_name": "Mirum Pharmaceuticals, Inc.",
  "success": true,
  "trials": [
    {
      "nct_id": "NCT04168385",
      "title": "MRX-800: A Long-Term Safety Study of Maralixibat in the Treatment of Cholestatic Liver Disease in Subjects Who Previously Participated in a Maralixibat Study",
      "status": "COMPLETED",
      "phase": "PHASE2",
      "condition": "Cholestatic Liver Disease",
      "start_date": "2020-01-16",
      "completion_date": "2024-09-04",
      "enrollment": 0,
      "sponsor": "Mirum Pharmaceuticals, Inc."
    },
    {
      "nct_id": "NCT00007020",
      "title": "Compassionate Treatment of Patients With Inborn Errors of Bile Acid Metabolism With Cholic Acid",
      "status": "COMPLETED",
      "phase": "PHASE3",
      "condition": "Infantile Refsum's Disease, Zellweger Syndrome, Adrenoleukodystrophy, Peroxisomal Disorders, Cholestasis",
      "start_date": "1992-01",
      "completion_date": "2009-12",
      "enrollment": 0,
      "sponsor": "Mirum Pharmaceuticals, Inc."
    },
    {
      "nct_id": "NCT02321306",
      "title": "An Open-label Study to Evaluate the Long-term Safety and Tolerability of LUM001 in Patients With Primary Biliary Cirrhosis",
      "status": "WITHDRAWN",
      "phase": "PHASE2",
      "condition": "Primary Biliary Cirrhosis",
      "start_date": "2015-05",
      "completion_date": "2018-03",
      "enrollment": 0,
      "sponsor": "Mirum Pharmaceuticals, Inc."
    },
    {
      "nct_id": "NCT04729751",
      "title": "A Study to Evaluate the Safety and Tolerability of Maralixibat in Infant Participants With Cholestatic Liver Diseases Including Progressive Familial Intrahepatic Cholestasis (PFIC) and Alagille Syndrome (ALGS).",
      "status": "COMPLETED",
      "phase": "PHASE2",
      "condition": "Progressive Familial Intrahepatic Cholestasis, Alagille Syndrome, Cholestatic Liver Disease",
      "start_date": "2021-09-09",
      "completion_date": "2024-12-17",
      "enrollment": 0,
      "sponsor": "Mirum Pharmaceuticals, Inc."
    },
    {
      "nct_id": "NCT04524390",
      "title": "Evaluation of Maralixibat in Biliary Atresia Response Post-Kasai",
      "status": "COMPLETED",
      "phase": "PHASE2",
      "condition": "Biliary Atresia",
      "start_date": "2021-07-08",
      "completion_date": "2024-02-07",
      "enrollment": 0,
      "sponsor": "Mirum Pharmaceuticals, Inc."
    },
    {
      "nct_id": "NCT01115582",
      "title": "Efficacy of To Be Marketed (TBM) Cholic Acid Capsules Used to Treat Children With Inborn Errors of Bile Acid Synthesis",
      "status": "COMPLETED",
      "phase": "PHASE3",
      "condition": "Inborn Errors of Bile Acid Synthesis",
      "start_date": "2010-04",
      "completion_date": "2010-08",
      "enrollment": 0,
      "sponsor": "Mirum Pharmaceuticals, Inc."
    },
    {
      "nct_id": "NCT02160782",
      "title": "Safety and Efficacy Study of LUM001 (Maralixibat) With a Drug Withdrawal Period in Participants With Alagille Syndrome (ALGS)",
      "status": "COMPLETED",
      "phase": "PHASE2",
      "condition": "Alagille Syndrome",
      "start_date": "2014-10-28",
      "completion_date": "2020-05-28",
      "enrollment": 0,
      "sponsor": "Mirum Pharmaceuticals, Inc."
    },
    {
      "nct_id": "NCT05050136",
      "title": "A Study to Evaluate Efficacy and Safety of an Investigational Drug Named Volixibat in Patients With Itching Caused by Primary Biliary Cholangitis",
      "status": "RECRUITING",
      "phase": "PHASE2",
      "condition": "Primary Biliary Cholangitis, PBC",
      "start_date": "2021-09-22",
      "completion_date": "2027-07",
      "enrollment": 0,
      "sponsor": "Mirum Pharmaceuticals, Inc."
    },
    {
      "nct_id": "NCT02131623",
      "title": "Validation of the Itch Reported Outcome (ItchRO) Diaries in Pediatric Cholestatic Liver Disease",
      "status": "COMPLETED",
      "phase": "",
      "condition": "Alagille Syndrome, Progressive Familial Intrahepatic Cholestasis",
      "start_date": "2014-07",
      "completion_date": "2015-03",
      "enrollment": 0,
      "sponsor": "Mirum Pharmaceuticals, Inc."
    },
    {
      "nct_id": "NCT02475317",
      "title": "Study to Assess the Relative Potency of Multiple Oral Doses of LUM001 and SHP626 in Overweight and Obese Adults as Assessed by Fecal Bile Acid Excretion",
      "status": "COMPLETED",
      "phase": "PHASE1",
      "condition": "Healthy Volunteers",
      "start_date": "2015-06-01",
      "completion_date": "2015-12-01",
      "enrollment": 0,
      "sponsor": "Mirum Pharmaceuticals, Inc."
    }
  ],
  "summary": {
    "total_trials": 34,
    "by_phase": {
      "PHASE2": 17,
      "PHASE3": 8,
      "": 5,
      "PHASE1": 3,
      "PHASE4": 1
    },
    "by_status": {
      "COMPLETED": 21,
      "WITHDRAWN": 2,
      "RECRUITING": 5,
      "ENROLLING_BY_INVITATION": 1,
      "ACTIVE_NOT_RECRUITING": 2,
      "APPROVED_FOR_MARKETING": 1,
      "TERMINATED": 2
    },
    "active_trials": 8,
    "completed_trials": 21,
    "conditions": [
      "Acid Sphingomyelinase Deficiency, Ceroid Lipofuscinosis, Neuronal, 2, Cerebrotendinous Xanthomatosis, Fabry Disease, GM1 Gangliosidosis, Gaucher Disease, Lysosomal Acid Lipase Deficiency, Metachromatic Leukodystrophy, Mucopolysaccharidosis II, Mucopolysaccharidosis III-B, Mucopolysaccharidosis IV A, Mucopolysaccharidosis VI, Mucopolysaccharidosis VII, Niemann-Pick Disease, Type C",
      "Alagille Syndrome",
      "Alagille Syndrome, Progressive Familial Intrahepatic Cholestasis",
      "Bile Acid Synthesis Defect",
      "Bile Acid Synthesis Disorders",
      "Biliary Atresia",
      "CTX",
      "Cholestatic Liver Disease",
      "Cholestatic Liver Disease (Except ALGS, PFIC, PBC and PSC)",
      "Fragile X Syndrome",
      "Healthy Volunteers",
      "Inborn Errors of Bile Acid Synthesis",
      "Infantile Refsum's Disease, Zellweger Syndrome, Adrenoleukodystrophy, Peroxisomal Disorders, Cholestasis",
      "Intrahepatic Cholestasis of Pregnancy",
      "Non-Alcoholic Steatohepatitis",
      "PBC, Primary Biliary Cirrhosis",
      "Primary Biliary Cholangitis, PBC",
      "Primary Biliary Cirrhosis",
      "Primary Sclerosing Cholangitis",
      "Primary Sclerosing Cholangitis (PSC)",
      "Progressive Familial Intrahepatic Cholestasis (PFIC)",
      "Progressive Familial Intrahepatic Cholestasis, Alagille Syndrome, Cholestatic Liver Disease"
    ],
    "lead_stage": "commercial"
  },
  "provenance": {
    "source": "ClinicalTrials.gov API v2",
    "timestamp": "2026-01-29T12:20:00.264557",
    "search_query": "Mirum Pharmaceuticals, Inc.",
    "url": "https://clinicaltrials.gov/search?term=Mirum+Pharmaceuticals,+Inc."
  }
}